TTK and head and neck squamous cell carcinoma: Our data demonstrate that HNSCC cells are highly sensitive to TTK inhibition with low nanomolar concentrations of BAY1217389, a potent TTK inhibitor currently in early phase I studies in combination with paclitaxel (39).